FDA Designates Aurobindo Formulation Unit’s Operations as Official Action Indicated
The U.S. Food and Drug Administration (FDA) has classified a formulation manufacturing unit operated by a subsidiary of Indian pharmaceutical giant Aurobindo Pharma as “Official Action Indicated” (OAI), signaling significant compliance issues that could impact the unit’s ability to export products to the United States. The designation, which typically follows a regulatory inspection finding serious…